昆泰胶囊联合醋酸亮丙瑞林治疗子宫内膜异位症的疗效及安全性：系统评价和荟萃分析方案。
The efficacy and safety of Kuntai capsule combined with leuprorelin acetate in the treatment of endometriosis: A protocol for systematic review and meta-analysis.
机构信息
Hengshui People's Hospital, Hengshui, Hebei Province.
First Hospital of Zibo City, Zibo, Shandong Province, China.
出版信息
Medicine (Baltimore). 2021 Mar 19;100(11):e25080. doi: 10.1097/MD.0000000000025080.
BACKGROUND
Endometriosis (EMS) is one of the common diseases in women, which seriously affects the quality of life of women. Leuprorelin acetate can control the development of EMS, but long-term use can cause perimenopausal symptoms in women. Clinical studies have shown that Kuntai capsule combined with leuprorelin acetate is effective in the treatment of EMS, which can relieve perimenopausal symptoms, but it lacks of evidence-based medical evidence. Therefore, this study aims to systematically evaluate the efficacy and safety of Kuntai capsule combined with leuprorelin acetate in the treatment of EMS.
METHODS
CNKI, VIP, Wanfang, Chinese Biomedical Literature Database, PubMed, The Cochrance Library, Embase, Web of Science, and other databases were searched by computer to collect randomized controlled trials of Kuntai capsule combined with leuprorelin acetate in the treatment of EMS. The retrieval time was from the establishment of the database to February 2021. Two researchers screened the literatures and extracted the data and meta-analysis was performed using RevMan 5.3 software.
RESULTS
This study evaluated the efficacy and safety of Kuntai capsule combined with leuprorelin acetate in the treatment of EMS by clinical effective rate, serum sex hormone levels estradiol, follicle-stimulating hormone, luteinizing hormone, visual analogue scale, Kupperman score and incidence of adverse reactions.
CONCLUSION
This study will provide reliable evidence-based evidence for the clinical application of Kuntai capsule combined with leuprorelin acetate in the treatment of EMS.
ETHICS AND DISSEMINATION
Private information from individuals will not be published. This systematic review also does not involve endangering participant rights. Ethical approval will not be required. The results may be published in a peer-reviewed journal or disseminated at relevant conferences.
OSF REGISTRATION NUMBER
DOI 10.17605/OSF.IO/AZU47.
背景
子宫内膜异位症（EMS）是一种常见的妇科疾病，严重影响女性的生活质量。醋酸亮丙瑞林能控制 EMS 的发展，但长期使用会导致女性出现围绝经期症状。临床研究表明，坤泰胶囊联合醋酸亮丙瑞林治疗 EMS 有效，能缓解围绝经期症状，但缺乏循证医学证据。因此，本研究旨在系统评价坤泰胶囊联合醋酸亮丙瑞林治疗 EMS 的疗效和安全性。
方法
计算机检索中国知网、维普、万方、中国生物医学文献数据库、PubMed、The Cochrance Library、Embase、Web of Science 等数据库，搜集坤泰胶囊联合醋酸亮丙瑞林治疗 EMS 的随机对照研究，检索时限均为建库至 2021 年 2 月。由 2 位研究者筛选文献、提取资料，并采用 RevMan 5.3 软件进行 Meta 分析。
结果
本研究通过临床有效率、血清性激素水平雌二醇、卵泡刺激素、黄体生成素、视觉模拟评分法、Kupperman 评分、不良反应发生率评价坤泰胶囊联合醋酸亮丙瑞林治疗 EMS 的疗效和安全性。
结论
本研究将为坤泰胶囊联合醋酸亮丙瑞林治疗 EMS 的临床应用提供可靠的循证医学证据。
伦理与传播
本研究不会公开个人信息。本系统评价也不会危及参与者的权利。不需要伦理批准。研究结果可能会发表在同行评议的期刊上，或在相关会议上传播。
OSF 注册号：DOI 10.17605/OSF.IO/AZU47。
Zotero 插件